

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



ASX Release

9 February 2026

BOARD CHANGES

MELBOURNE, AUSTRALIA 9 February 2026: Arovella Therapeutics Limited (ASX: ALA) (**Arovella** or the **Company**), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, today announces that Dr Elizabeth Stoner will be retiring as Non-Executive Director and Interim Chair of the Company, and Mr Gary Phillips will retire as Non-executive Director effective 9 February 2026. Dr Stoner has served as Interim Chair of Arovella since 1 July 2025 and as Non-Executive Director since 10 November 2021. Mr Phillips has served as Non-Executive Director since 1 July 2022.

Given the significant changes to the Board, the Company will conduct a skills review. Following completion of the skills review, the Company will provide additional updates relating to the appointment of a new Chair.

Arovella's CEO and MD, Dr Michael Baker, said: "Dr Stoner played a pivotal role in shaping Arovella during its pivot to a cell therapy company, and was instrumental as the Company took its CAR-iNKT cell platform from the preclinical to clinical stage. We thank Elizabeth for taking on the interim Chair role two times and for being an outstanding advocate of the Company. The Company was also incredibly fortunate to have the input of Gary over his tenure, and Arovella benefited greatly from his outstanding business acumen and drug development experience. The Company wishes Liz and Gary continued success for their future endeavors and appreciates all they have done to enable the Company to reach the IND-ready stage. Following the recent acceptance of its IND, the Company is looking forward to dosing the first patient with ALA-101 and progressing its solid tumour technology, ALA-105. Both Liz and Gary played a key role in making that happen. Lastly, we look forward to providing updates relating to the board skills analysis and the appointment of a new Chair."

Dr Stoner said: "This was a very difficult decision, and it has been a privilege to serve as both a Non-Executive Director and Interim Chair of Arovella. The team is brilliant and should be immensely proud of the progress the Company has made, particularly in getting the IND accepted for ALA-101. I wish the team every success moving forward."

Mr Gary Phillips commented: "During the nearly 3 years I served on the Board, Arovella has built an exceptional team of people and advanced its technology through to acceptance of an IND for its first product. The Company is in a terrific position, and I have confidence that they will continue to grow in a positive direction as they look to dose the first patient with ALA-101. It is a very exciting time for the Company."

This announcement has been authorised for release by the Company's Board of Directors.

For further information, please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director Arovella Therapeutics Ltd

Tel +61 (0) 403 468 187

investor@arovella.com

NOTES TO EDITORS:**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α -GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **α GalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.

Not for Distribution or Release in the United States

This announcement may not be distributed or released in the United States. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold under the Placement or SPP have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "**U.S. Securities Act**") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares under the Placement or SPP may not be offered or sold, directly or indirectly, to any person in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. New Shares issued under the Placement or SPP described in this announcement may not be offered or sold, directly or indirectly, to any person in the United States or any person that is acting for the account or benefit of a person in the United States.